Pancreatic Cancer Research

ResearcherEmory UniversityNo recent work listed

Walid Labib Shaib

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9388-0446; OpenAlex author ID A5064900192. Sources: ClinicalTrials.gov.

Their work

Papers
16 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2016: 3 papers, 1 trial · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 4 papers · 2021: 1 paper · 2022: none · 2023: 3 papers

Papers 16

  1. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Co-author DOI 10.1016/j.ejca.2023.02.030↗
  2. Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002227↗
  3. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  4. Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis. Co-author DOI 10.1097/mpa.0000000000001788↗
  5. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Co-author DOI 10.1016/j.jgo.2019.10.012↗
  6. Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes. Co-author DOI 10.1097/mpa.0000000000001502↗
  7. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001584↗
  8. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Co-author DOI 10.1172/jci.insight.130362↗
  9. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Co-author DOI 10.1002/cncr.31787↗
  10. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Co-author DOI 10.1002/ijc.32227↗
  11. Induction Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001353↗
  12. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Co-author DOI 10.1634/theoncologist.2017-0487↗
  13. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. First author DOI 10.1002/cncr.30944↗
  14. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Co-author DOI 10.1016/j.ejca.2015.10.057↗
  15. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). Co-author DOI 10.1016/j.ijrobp.2016.05.010↗
  16. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Co-author DOI 10.1634/theoncologist.2015-0316↗

Trials 1

  1. Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer Principal investigator NCT02581215↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bassel F. El‐Rayes · 15 shared papers, 2016–2023 · strength 1.51
  2. Olatunji Boladale Alese · 9 shared papers, 2016–2023 · strength 0.93
  3. Mehmet Akce · 7 shared papers, 2019–2023 · strength 0.79
  4. Shishir Kumar Maithel · 7 shared papers, 2016–2020 · strength 0.56
  5. Christina Sing-Ying Wu · 5 shared papers, 2018–2023 · strength 0.54
  6. Juan Manuel Sarmiento · 5 shared papers, 2016–2020 · strength 0.41
  7. David A. Kooby · 5 shared papers, 2016–2020 · strength 0.38
  8. Jerome Carl Landry · 4 shared papers, 2016–2019 · strength 0.31
  9. Pretesh R Patel · 3 shared papers, 2019–2020 · strength 0.29
  10. Gregory B. Lesinski · 3 shared papers, 2017–2020 · strength 0.28
  11. Ganji Purnachandra Nagaraju · 3 shared papers, 2016–2019 · strength 0.26
  12. Astrid Belalcazar · 3 shared papers, 2017–2020 · strength 0.25
  13. Bert H. O’Neil · 1 shared paper, 2023 · strength 0.17
  14. Patrick Joseph Loehrer · 1 shared paper, 2023 · strength 0.17
  15. Tanios Bekaii‐Saab · 1 shared paper, 2023 · strength 0.17
  16. Steven J. Cohen · 1 shared paper, 2023 · strength 0.17
  17. Lana E. Khalil · 1 shared paper, 2023 · strength 0.17
  18. Michelle Dian Reid · 1 shared paper, 2023 · strength 0.17
  19. Sujata R. Kane · 2 shared papers, 2018–2019 · strength 0.17
  20. Matthew R. Farren · 2 shared papers, 2017–2020 · strength 0.16
  21. Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
  22. Raëf Abdallah · 1 shared paper, 2023 · strength 0.12
  23. Jin‐Young Jang · 1 shared paper, 2023 · strength 0.12
  24. Giuseppe Malleo · 1 shared paper, 2023 · strength 0.12
  25. Gregory C. Wilson · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.